Measles/Rubella Clinical Trial
Official title:
Freeze-dried Live Attenuated Measles and Rubella Combined Vaccine "Takeda" Specified Drug-use Survey of Vaccinees After the Second Vaccination
The purpose of this survey is to assess the safety of freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) (freeze-dried live attenuated measles and rubella combined vaccine "Takeda") in terms of the occurrence of unknown/known adverse drug reactions and factors that may influence the safety of vaccinees after the second vaccination.
This survey was designed to assess the safety of freeze-dried live attenuated measles and
rubella combined vaccine (Schwarz FF-8 strain/TO-336strain) (freeze-dried live attenuated
measles and rubella combined vaccine "Takeda") in terms of the occurrence of unknown/known
adverse drug reactions and factors that may influence safety after the second vaccination.
Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336
strain) is dissolved in 0.7 mL of accompanying reconstitution fluid (water for injection
[Japanese Pharmacopoeia]), wherein a 0.5-mL portion is typically administered subcutaneously
as a single dose.
In addition, freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8
strain/TO-336 strain) should be used in accordance with the "Regulations for Vaccination" and
the "Guidelines for Routine Vaccination."
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02151773 -
Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Special Drug Use Surveillance of Vaccinees After the First Vaccination
|
N/A |